
In the Claims:

Please amend claims 32, 36 and 38-44 as indicated. All previously and currently pending claims are included herein.

1-10. (Previously cancelled)

- 11. (Previously Presented) A method for protecting glial cells or non-dopaminergic neural cells in a mammal against death from neural injury or disease comprising the step of administering to said mammal a neuroprotective amount of a peptide selected from the group consisting of (a) the tripeptide gly-pro-glu (GPE); (b) the dipeptide gly-pro (GP); and (c) the dipeptide pro-glu.
- 12. (Previously Presented) A method as claimed in claim 11 wherein the peptide administered is GPE.
- 13. (Previously Presented) A method as claimed in claim 12 wherein GPE is administered to protect non-dopaminergic neurons against death.
- 14. (Previously Presented) A method as claimed in claim 12 wherein GPE is administered to protect glial cells against death.
- 15. (Previously Presented) A method as claimed in claim 13 wherein the dosage range of GPE administered is from about 1 µg to about 1000 mg of GPE per kg of body weight of the mammal.
- 16. (Previously Presented) A method as claimed in claim 14 wherein the dosage range of GPE administered is from about 1 µg to about 1000 mg of GPE per kg of body weight of the mammal.
- 17. (Previously Presented) A method as claimed in claim 12, further comprising applying an electrophoretic procedure in aid of said administration of GPE.



- The method of claim 11, wherein said peptide is administered (Previously Presented) 18. via maternal circulation.
- A method as claimed in claim 12 in which a neuroprotective (Previously Presented) 19. amount of GPE is administered prior to an event considered likely to lead to an injury to glial cells or non-dopaminergic neural cells.
- The method of claim 19, wherein said event comprises cardiac (Previously Presented) 20. surgery.
- The method of claim 19, wherein said event comprises brain 21. (Previously Presented) surgery.
- The method of claim 19, wherein said event comprises 22. (Previously Presented) parturition.
- The method of claim 12, wherein said peptide is administered 23. (Previously Presented) via maternal circulation.
- A method as claimed in claim 19, wherein said event is 24. (Previously Presented) considered likely to lead to an injury to glial cells.
- A method as claimed in claim 12 in which GPE is administered (Previously Presented) 25. subsequent to injury or disease affecting glial cells or non-dopaminergic neural cells but prior to death of said cells.
- A method as claimed in claim 25, wherein said injury or disease (Previously Presented) 26. affects non-dopaninergic neural cells.

- 27. (Previously Presented) A method as claimed in claim 25, wherein said injury or disease affects glial cells.
- 28 (Previously Presented) A method as claimed in claim 25, wherein said GPE is administered to protect glial or non-dopaminergic neural cells against death through injury, and wherein said GPE is administered for up to 100 hours subsequent to said injury.
- 29. (Previously Presented) A method as claimed in claim 28 in which GPE is administered from 0.5 to 8 hours subsequent to said injury.
- 30. (Previously Presented) A method as claimed in claim 12 in which GPE is administered directly to where the cell bodies of glial cells or non-dopaminergic neural cells to be protected are located.
- 31. (Previously Presented) A method of claim 30, wherein said cells to be protected comprise glial cells.
- 32. (Currently Amended) A method as claimed in claim 30 wherein GPE is administered directly to the brain or cerebrospinal fluid by cerebro-ventricular injection, by injection into the cerebral parenchyma or through a surgically inserted shunt into the lateral cerebro cerebral ventricle of the brain.
- 33. (Previously Presented) A method as claimed in claim 30 wherein GPE is administered by cerebro-ventricular injection.
- 34. (Previously Presented) A method as claimed in claim 12 wherein GPE is administered in combination with artificial cerebrospinal fluid.
- 35. (Previously Presented) A method as claimed in claim 33 wherein GPE is administered in combination with artificial cerebrospinal fluid.

-4-

- 36 (Currently amended) A method as claimed in claim 12, wherein GPE is administered through an introvenous intravenous, oral, rectal, nasal, subcutaneous, inhalation, intraperitoneal or intranscular route.
- 37. (Previously presented) A method as claimed in claim 36 wherein GPE is administered by intraperitoneal injection.
- 38. (Currently amended) The method of claim 11 wherein said neural <u>injury damage</u> is hypoxic neural <u>injury damage</u>.
- 39. (Currently amended) The method of claim 11 wherein said neural <u>injury damage</u> is ischemic neural <u>injury damage</u>.
- 40 (Currently amended) The method of claim 38 wherein said hypoxic <u>injury</u> damage results from stroke or cardiac bypass surgery.
- 41. (Currently amended) The method of claim 39 wherein said ischemic <u>injury damage</u> results from stroke or cardiac bypass surgery.
- 42. (Currently amended) A method of treating <u>injury damage</u> in a mammal comprising administering an effective amount of a peptide selected from the group consisting of gly-pro-glu, gly-pro, and pro-glu.
- 43. (Currently amended) The method of claim 15, wherein said neural <u>injury damage</u> is selected from the group consisting of hypoxic neural <u>injury damage</u>, ischemic neural <u>injury damage</u> and traumatic injury.
- 44. (Currently amended) The method of claim 16, wherein said hypoxic neural <u>injury damage</u> or said ischemic neural <u>injury damage</u> is associated with one or more of stroke and cardiac bypass surgery.

- 5 -

- 45. (Previously presented) The method of claim 11, wherein said glial cells or non-dopaminergic neural cells are central nervous system cells.
- 46. (Previously presented) The method of claim 11, wherein said glial cells or non-dopaminergic neural cells are peripheral nervous system cells.